European Commission Approves GSK's Exdensur for Severe Asthma and CRSwNP
Summary
GSK's Exdensur, an ultra-long-acting biologic, received European Commission approval for severe asthma and chronic rhinosinusitis with nasal polyps, expanding its market presence after recent approvals in other major regions.
Key Events
-
EU Regulatory Approval
The European Commission approved Exdensur (depemokimab) as an add-on maintenance treatment for severe asthma with type 2 inflammation and as an add-on therapy for severe chronic rhinosinusitis with nasal polyps (CRSwNP).
-
Novel Ultra-Long-Acting Biologic
Exdensur is the first and only ultra-long-acting biologic in the EU for these conditions, offering a convenient twice-yearly dosing regimen.
-
Strong Clinical Data
The approval is supported by data from four phase III trials (SWIFT and ANCHOR) demonstrating statistically significant and clinically meaningful efficacy in reducing asthma exacerbations and improving CRSwNP symptoms.
-
Global Market Expansion
This EU approval follows recent marketing authorizations for Exdensur in the US (December 2025), UK (December 2025), and Japan (January 2026), establishing its presence in major global markets.
Analysis
The European Commission's approval of Exdensur (depemokimab) significantly expands the market for this novel ultra-long-acting biologic into the European Union. This drug, offering a twice-yearly dosing regimen, presents a competitive advantage and a new treatment option for millions of patients suffering from severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps. This key regulatory milestone, following recent approvals in the US, UK, and Japan, reinforces Exdensur's global market potential and strengthens GSK's leadership in respiratory medicine. The stock is currently trading near its 52-week high, and this positive news could further bolster investor confidence.
At the time of this filing, GSK was trading at $60.91 on NYSE in the Life Sciences sector, with a market capitalization of approximately $120.1B. The 52-week trading range was $32.38 to $60.37. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.